Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.60 |
| ▸ | GNPAT | O15228 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798322 | 0.97 | OPRK1 (0.61) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL29798078 | 0.97 | OPRK1 (0.58) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL31152919 | 0.96 | OPRK1 (0.63) | OPRK1NPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29733679 | 0.95 | OPRK1 (0.57) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL31181190 | 0.95 | OPRK1 (0.57) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL30880418 | 0.95 | OPRK1 (0.57) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL30957128 | 0.94 | OPRK1 (0.68) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL30733256 | 0.93 | OPRK1 (0.58) | OPRK1NPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL30957135 | 0.93 | OPRK1 (0.69) | OPRK1GNPATNPY1RNPY2RNPY4R | |
| SCHEMBL30957126 | 0.93 | OPRK1 (0.69) | OPRK1GNPATNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRK1 4730/4885GNPAT 1529/4885NPY1R 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.